Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Change in Accured Expenses: 2023-2025

Historic Change in Accured Expenses for Contineum Therapeutics (CTNM) over the last 3 years, with Sep 2025 value amounting to $351,000.

  • Contineum Therapeutics' Change in Accured Expenses fell 70.90% to $351,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $325,000, marking a year-over-year increase of 114.51%. This contributed to the annual value of $2.3 million for FY2024, which is 44.48% up from last year.
  • Per Contineum Therapeutics' latest filing, its Change in Accured Expenses stood at $351,000 for Q3 2025, which was up 444.12% from -$102,000 recorded in Q2 2025.
  • Contineum Therapeutics' Change in Accured Expenses' 5-year high stood at $2.9 million during Q4 2024, with a 5-year trough of -$2.9 million in Q1 2025.
  • For the 3-year period, Contineum Therapeutics' Change in Accured Expenses averaged around $116,727, with its median value being -$102,000 (2025).
  • In the last 5 years, Contineum Therapeutics' Change in Accured Expenses spiked by 283.05% in 2024 and then plummeted by 653.16% in 2025.
  • Over the past 3 years, Contineum Therapeutics' Change in Accured Expenses (Quarterly) stood at -$1.6 million in 2023, then spiked by 283.05% to $2.9 million in 2024, then tumbled by 70.90% to $351,000 in 2025.
  • Its Change in Accured Expenses was $351,000 in Q3 2025, compared to -$102,000 in Q2 2025 and -$2.9 million in Q1 2025.